Cyclerion Therapeutics
CYCN
77 hedge funds and large institutions have $41.8M invested in Cyclerion Therapeutics in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 24 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.77% less ownership
Funds ownership: 3.56% → 2.8% (-0.77%)
14% less funds holding
Funds holding: 90 → 77 (-13)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
82% less capital invested
Capital invested by funds: $237M → $41.8M (-$195M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.83M |
| 2 |
AC
AWH Capital
Dallas,
Texas
|
+$2.65M |
| 3 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
+$911K |
| 4 |
D.E. Shaw & Co
New York
|
+$760K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$707K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$27M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.7M |
| 3 |
SPC
Slate Path Capital
New York
|
-$10.7M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$4.66M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.84M |
CYCN Hedge Fund Activity: Q4 2019 in Review
77 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2019, worth a combined $41.8M — down 82% from $237M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CYCN and 16 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 22 added.
The largest buyer was EcoR1 Capital, adding an estimated $4.83M. The largest seller was Camber Capital Management, exiting entirely with an estimated $27M sold.
- 77 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2019, down from 90 in Q3 2019.
- Funds reported $41.8M of Cyclerion Therapeutics stock for Q4 2019, down 82% quarter-over-quarter.
- 16 funds opened new Cyclerion Therapeutics positions in Q4 2019 and 24 closed out, a net change of -8 holders.
- The largest Cyclerion Therapeutics buyer in Q4 2019 was EcoR1 Capital, an estimated $4.83M added.
- The largest Cyclerion Therapeutics seller in Q4 2019 was Camber Capital Management, an estimated $27M sold.
Based on aggregated 13F filings for Q4 2019.